Serum beta 2-M in asymptomatic HIV-infected patients treated with zidovudine. 1990

C M Mastroianni, and F Paoletti, and V Vullo, and S Delia, and F Sorice

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D001613 beta 2-Microglobulin An 11-kDa protein associated with the outer membrane of many cells including LYMPHOCYTES. It is the small subunit of MHC CLASS I MOLECULES. Association with beta 2-microglobulin is generally required for the transport of class I heavy chains from the endoplasmic reticulum to the cell surface. Beta 2-microglobulin is present in small amounts in serum, CEREBROSPINAL FLUID, and urine of healthy individuals, and to a much greater degree in the urine and plasma of patients with tubular PROTEINURIA, renal failure, or kidney transplants. Thymotaxin,beta 2 Microglobulin
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

C M Mastroianni, and F Paoletti, and V Vullo, and S Delia, and F Sorice
January 1998, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
C M Mastroianni, and F Paoletti, and V Vullo, and S Delia, and F Sorice
June 1991, Genitourinary medicine,
C M Mastroianni, and F Paoletti, and V Vullo, and S Delia, and F Sorice
January 1990, Scandinavian journal of infectious diseases,
C M Mastroianni, and F Paoletti, and V Vullo, and S Delia, and F Sorice
January 1990, The Journal of the American Board of Family Practice,
C M Mastroianni, and F Paoletti, and V Vullo, and S Delia, and F Sorice
February 1992, BMJ (Clinical research ed.),
C M Mastroianni, and F Paoletti, and V Vullo, and S Delia, and F Sorice
January 2004, Journal of clinical epidemiology,
C M Mastroianni, and F Paoletti, and V Vullo, and S Delia, and F Sorice
October 1991, AIDS (London, England),
C M Mastroianni, and F Paoletti, and V Vullo, and S Delia, and F Sorice
October 1994, Deutsche medizinische Wochenschrift (1946),
C M Mastroianni, and F Paoletti, and V Vullo, and S Delia, and F Sorice
December 1996, Antiviral therapy,
Copied contents to your clipboard!